Notes

The fund is called Catalyst Research and it is for research purposes only. The fund size is 0 and the time is 2026-09-16T08:16:07.468278+00:00. There are several news updates: TLX on Sunday, September 13, 2026, announced that the FDA approved Telix's brain cancer imaging drug Pixclara. AVO on Tuesday, September 8, 2026, announced its fiscal 2026 third quarter financial results. ABM on Tuesday, September 8, 2026, reported its fiscal third quarter 2026 results. ROIV on Tuesday, September 8, 2026, announced positive results from the Phocus study of mosliciguat. There are also several financial reports: UNFI filed a 10-K report on September 14, 2026, DRI filed a 10-K report on July 24, 2026, PPIH filed a 10-Q report on September 9, 2026, MRK filed a 10-Q report on August 7, 2026, and WLTH filed a 10-Q report on September 14, 2026. EPM announced its fiscal fourth quarter and full year results on Tuesday, September 15, 2026. IPHA filed a 6-K report on September 10, 2026. The HTTP status codes for KGF, ASKUL, IPHAnews, and SOBI are 200, with hashes 3313522fd352460d, e6f0d85c03a37ce6, 63c1ed7a93468887, and d719eca30b8a5a99, respectively. The research is set to end on September 17, and there is a conditional receipt for Sobi in Q1 2028. The monitors 165, 168, 167, 137, and 22 are preserved. The sources and dates are in the job script and journal. There are no orders.

The Catalyst fund is currently in research mode only, with a size of 0, as of September 16, 2026, at 06:31:09 UTC. The fund is tracking the following stocks: IONS, MIRM, GIS, and EAT, as well as CAG. The fund manager has reviewed the following SEC filings: IONS on September 4, 2026, MIRM on September 8, 2026, GIS on July 1, 2026, and EAT on August 12, 2026. On September 9, 2026, Barclays maintained an overweight rating on Ionis Pharmaceuticals, but lowered its price target to $85. GIS has a conference scheduled for September 8, 2026, at 19:00 UTC, and the fund manager will review the replay. The fund manager is also tracking earnings releases, including GIS on September 23, 2026, and EAT on October 28, 2026. The baseline estimates for GIS are an EPS of $3.00-3.20, organic growth of -1.5% to +0.5%, and savings of $750m. The fund manager has chosen to review EAT's investor day on September 17, 2026, and will reverify the first news release. The fund manager will record and validate stronger organic cash growth, but will reverify weaker or absent growth. There are no automatic trades, and the fund manager will verify full pipelines and early news. The fund is still in research mode only, with no orders, as of September 16, 2026, at 06:31:13 UTC.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 16, 2026, at 06:31:08 UTC. The fund manager reviewed the following SEC filings: CHWY's 10-Q filing on September 9, 2026, ASO's 10-Q filing on September 9, 2026, LOVE's 10-Q filing on September 10, 2026, and SFIX's 8-K filing on July 28, 2026. The manager also reviewed the following news releases: SAIL's announcement on September 9, 2026, KFY's announcement on September 9, 2026, and LOVE's announcement on September 15, 2026. Additionally, the manager checked the FDA's website for updates on GRAL, which has a meeting scheduled for September 23, 2026. The manager noted that SEC filings may lag behind news and will review the following upcoming events: new morning results on September 9 at 12:30, LOVE's results on September 10 at 12:30, and SFIX's results on September 24 at 12:30 after the September 23 AMC. The manager also noted that GRAL's panel on September 23 is not an approval event. The manager will use a strong cash position to record and validate trades, and a weak or early cash position to cash out and reverify trades. No automatic orders were placed.

The fund is called Catalyst Research and it is for research only. The size of the fund is 0 and the time is 2026-09-16T04:15:57.892279+00:00. There are several news updates: TLX on Sunday, September 13, 2026, announced that the FDA approved Telix's brain cancer imaging drug Pixclara. AVO on Tuesday, September 8, 2026, announced its fiscal 2026 third-quarter financial results. ABM on Tuesday, September 8, 2026, reported its fiscal third-quarter 2026 results. ROIV on Tuesday, September 8, 2026, announced positive results from the Phocus study of mosliciguat. There are also several financial reports: UNFI's 10-K report on September 14, 2026, DRI's 10-K report on July 24, 2026, PPIH's 10-Q report on September 9, 2026, MRK's 10-Q report on August 7, 2026, and WLTH's 10-Q report on September 14, 2026. Additionally, EPM reported its fiscal fourth-quarter and full-year results on Tuesday, September 15, 2026, and IPHA filed a 6-K report on September 10, 2026. The HTTP requests for KGF, ASKUL, IPHAnews, and SOBI were successful with hashes 3313522fd352460d, e6f0d85c03a37ce6, 63c1ed7a93468887, and d719eca30b8a5a99, respectively. The research is ongoing and no orders have been placed. The monitors for 165, 168, 167, 137, and 22 will be preserved. The sources and dates are available in the job script and journal. A decision will be made on September 17 regarding IPHA, and a receipt and Q1 2028 conditional decision will be made for Sobi.

The Catalyst fund is currently researching the stocks IONS, MIRM, GIS, and EAT, along with CAG, with a size of 0. As of September 16, 2026, at 02:16:07 UTC, the fund has noted the following: IONS filed a report with the Securities and Exchange Commission (SEC) on September 4, 2026, which can be found at https://www.sec.gov/Archives/edgar/data/874015/000114036126035802/ef20081690_8k.htm. MIRM filed a report with the SEC on September 8, 2026, which can be found at https://www.sec.gov/Archives/edgar/data/1759425/000175942526000047/mirm-20260902.htm. GIS filed a report with the SEC on July 1, 2026, which can be found at https://www.sec.gov/Archives/edgar/data/40704/000162828026046337/gis-20260701.htm. EAT filed a report with the SEC on August 12, 2026, which can be found at https://www.sec.gov/Archives/edgar/data/703351/000070335126000026/eat-20260810.htm. On September 9, 2026, Barclays maintained an overweight rating on Ionis Pharmaceuticals and lowered its price target to $85. GIS had a conference on September 8, 2026, at 19:00 UTC, which can be reviewed. The fund is waiting for GIS's earnings report on September 23, 2026, at 13:00 UTC, and will review the Q&A session. If GIS's organic cash is strong, the fund will record and validate the results, but if it is weak or absent, the fund will reverify the cash. The fund has a baseline estimate for GIS's FY27 EPS of $3.00-3.20, with organic growth of -1.5% to +0.5% and savings of $750 million. The fund has a frozen paper window from September 16 to September 21 and will not retune past tests. EAT is having an investor day on September 17, 2026, from 08:30 to 11:15 CT, and the fund will review it at 16:30 UTC. EAT's earnings call is scheduled for October 28, 2026, but the hour and first release time are unknown. The fund will review the earnings call at 16:30 UTC and reverify the first news. If EAT's organic cash is strong, the fund will record and independently validate the results, but if it is weak or absent, the fund will reverify the cash. The fund has a frozen T5 holdout of -19.2065% and will not make automatic trades. The fund is currently in research mode only and has not placed any orders as of September 16, 2026, at 02:16:10 UTC.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 16, 2026, at 02:16:07 UTC. The fund reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. It also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the fund looked at news from SAIL, KFY, and LOVE, which were released on September 9, 2026, and September 15, 2026. The fund also checked for FDA updates, specifically a meeting on September 23, 2026, regarding GRAL, which is not an approval meeting. The fund will review new results on September 9, 2026, at 12:30, and on September 10, 2026, at 12:30 for LOVE, and on September 24, 2026, at 12:30 for SFIX, after the September 23, 2026, meeting. The fund uses a system where strong cash positions are recorded and validated, while weak or early positions are cashed out and reverified. No automatic orders were placed.

The fund is called Catalyst Research and it has a size of 0. It is compacting receipts and the origins are in the PRE91108 archive. This was done on 2026-09-16T01:31:06.215636+00:00. There are 11 panels of information. Panel 0 has 70 characters and a sha, or secure hash algorithm, of a7bd19f72a4b7147. Panel 1 has 101 characters and a link to the SEC website for HITI on 2026-09-14. Panel 2 has 98 characters and a link to the SEC website for BFRI on 2026-09-14. Panel 3 has 216 characters and a preview of Dave & Buster's second quarter 2026 report. Panel 4 has 246 characters and mentions TSM and DATA.L S. Panel 5 has 260 characters and mentions CAN and PLAY. Panel 6 has 353 characters and talks about improved organic cash and credible clinical evidence. Panel 7 has 160 characters and mentions EGTX and a link to the mfn website. Panel 8 has 206 characters and mentions EGTX chosen reviews. Panel 9 has 99 characters and a link to the usitc website for BFRI. Panel 10 has 341 characters and mentions BFRI and a link to the federal register website. The raw sha is ba3d9c38b01d0333bc167559fea399f4cd0a59819999d4bb0b83c9b6b2cd9019.

The fund is called Catalyst Research and it is for research purposes only. The fund size was checked at 0 UTC on 2026-09-16T00:15:57.176494+00:00. There were several news updates, including: TLX on Sunday, September 13, 2026, about the FDA approving Telix's brain cancer imaging drug Pixclara, which can be found at https://telixpharma.com/news-views/fda-approves-telixs-brain-cancer-imaging-drug-pixclara/; AVO on Tuesday, September 8, 2026, about Mission Produce's fiscal 2026 third-quarter financial results, which can be found at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial; ABM on Tuesday, September 8, 2026, about ABM's fiscal third-quarter 2026 results, which can be found at https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results; and ROIV on Tuesday, September 8, 2026, about Roivant's positive results from the Phocus study of mosliciguat, which can be found at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat. There were also several financial filings, including: UNFI's 10-K filing on 2026-09-14, which can be found at 0001020859-26-000025/unfi-20260801.htm; DRI's 10-K filing on 2026-07-24, which can be found at 0000940944-26-000025/dri-20260531.htm; PPIH's 10-Q filing on 2026-09-09, which can be found at 0001437749-26-029988/ppih20260731_10q.htm; MRK's 10-Q filing on 2026-08-07, which can be found at 0000310158-26-000212/mrk-20260630.htm; and WLTH's 10-Q filing on 2026-09-14, which can be found at 0001628280-26-061848/wlth-20260731.htm. Additionally, there were updates from EPM on Tuesday, September 15, 2026, about Evolution Petroleum's fiscal fourth-quarter and full-year results, which can be found at https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-reports-fiscal-fourth-quarter-and-full-0, and IPHA's 6-K filing on 2026-09-10, which can be found at 0001628280-26-061214/a260910_6k.htm. The HTTP status codes for KGF, ASKUL, IPHAnews, and SOBI were all 200, with hashes 3313522fd352460d, e6f0d85c03a37ce6, 63c1ed7a93468887, and d719eca30b8a5a99, respectively. The research is ongoing, with a focus on strong and new information, and a plan to read originals and validate them, while weak or absent information will be verified and cash will be used to reverify. There are also plans to preserve monitors 165, 168, 167, 137, and 22, and to check IPHA on September 17, and Sobi receipt and Q1 2028 conditional. The sources and dates can be found in the job script and journal, and there are no orders at this time.

The Catalyst fund is currently researching the stocks IONS, MIRM, GIS, and EAT, as well as CAG, with a size of 0. The fund's status was last updated on September 15, 2026, at 22:15:56 UTC. The fund manager has been reviewing SEC filings for these stocks, including IONS on September 4, MIRM on September 8, GIS on July 1, and EAT on August 12. A news scan found the headline that Barclays maintains an overweight rating on Ionis Pharmaceuticals and lowers its price target to $85 on September 9. The GIS company had a conference on September 8, which has already passed, and the fund manager will review the replay. The fund manager is also waiting for the earnings report from GIS on September 23, which will include a Q&A session at 13:00 UTC. The fund's baseline expectations for GIS are an EPS of $3.00-3.20 for the fiscal year 2027, with organic growth of -1.5% to +0.5% and savings of $750 million. The fund manager has also been tracking EAT, which had an investor day on September 17 and will have an earnings call on October 28. The fund's strategy is to record and validate stronger organic cash growth and to reverify weaker or absent growth. The fund manager has frozen the paper window from September 16 to September 21 and has set a calendar out of sample with a return of 0.567% and a stress test of -2.405%. The fund manager has chosen to review the EAT investor day on September 17 and the earnings call on October 28. The fund's research is ongoing, and no orders have been placed yet, with the last update on September 15, 2026, at 22:15:59 UTC.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 15, 2026, at 22:15:57 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, LOVE on September 10, 2026, and SFIX on July 28, 2026. The manager also reviewed the following RSS feeds: SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 15, 2026. Additionally, the manager checked the FDA website for information on GRAL, which has a meeting scheduled for September 23, 2026. The manager noted that the SEC filings may lag behind the news and will review the following updates: new morning results on September 9 at 12:30, LOVE on September 10 at 12:30, and SFIX on September 24 at 12:30 after the September 23 AMC. The manager also noted that the GRAL panel on September 23 is not an approval. The manager will use a strong cash position to record and validate, and a weak or early position to cash and reverify. No automatic orders were placed.

The fund is called Catalyst Research and it is for research purposes only. The fund size is 0 and the time is 2026-09-15T20:15:57.171286+00:00. There are several news updates: TLX on Sunday, September 13, 2026, announced that the FDA approved Telix's brain cancer imaging drug Pixclara. AVO on Tuesday, September 8, 2026, announced its fiscal 2026 third quarter financial results. ABM on Tuesday, September 8, 2026, reported its fiscal third quarter 2026 results. ROIV on Tuesday, September 8, 2026, announced positive results from the Phocus study of mosliciguat. There are also several financial reports: UNFI's 10-K report on September 14, 2026, DRI's 10-K report on July 24, 2026, PPIH's 10-Q report on September 9, 2026, MRK's 10-Q report on August 7, 2026, and WLTH's 10-Q report on September 14, 2026. Additionally, EPM declared a $0.12 per share cash dividend on Thursday, September 10, 2026, and IPHA filed a 6-K report on September 10, 2026. The HTTP requests for KGF, ASKUL, IPHAnews, and SOBI were successful with hashes dda88bf6ef8ad805, e6f0d85c03a37ce6, 63c1ed7a93468887, and d719eca30b8a5a99, respectively. The research will continue on IPHA until September 17 and on Sobi until Q1 2028, conditional on receipt. The monitors for 165, 168, 167, 137, and 22 will be preserved. There are no orders and the sources and dates are recorded in the job script and journal. The research is classified as strong and new, and the originals should be read and validated, while weak or absent research should be verified and cashed.

The Catalyst fund is for research only on IONS, MIRM, GIS, and EAT, with no current size. As of September 15, 2026, at 18:01:00 UTC, the fund has the following notes: IONS filed a report with the SEC on September 4, 2026. MIRM filed a report with the SEC on September 8, 2026. GIS filed a report with the SEC on July 1, 2026. EAT filed a report with the SEC on August 12, 2026. On September 9, 2026, Barclays maintained an overweight rating on Ionis Pharmaceuticals and lowered its price target to $85. GIS had a conference on September 8, 2026, at 19:00 UTC. The fund will review earnings on September 23, 2026, at 13:00 UTC. For GIS, stronger organic cash flow will be recorded and validated, while weaker or absent cash flow will require re-verification. The baseline for July 1, 2026, was a FY27 EPS of $3.00-3.20, with organic growth of -1.5% to +0.5% and savings of $750 million. EAT will have an investor day on September 17, 2026, and an earnings call on October 28, 2026. The fund will review these events at 16:30 UTC on the respective days. The fund has a frozen paper window from September 16 to September 21, with a calendar out-of-sample performance of +0.567% and stress of -2.405%. The fund will not automatically enter trades and will not retune past tests. The fund has four SEC filings, one discovery, and two GIS and EAT events to verify. As of September 15, 2026, at 18:01:03 UTC, the fund remains in research-only mode with no orders.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 15, 2026, at 18:01:00 UTC. The fund reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. It also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the fund looked at RSS feeds from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 15, 2026. The fund also checked the FDA website for information on GRAL, which had a panel meeting scheduled for September 23, 2026, but this was not an approval meeting. The fund uses a system where strong cash positions are recorded and validated, while weak or early positions are verified again. No automatic orders were made. The fund will review new morning results on September 9 at 12:30, LOVE on September 10 at 12:30, and SFIX on September 24 at 12:30, after the September 23 AMC.

A fund manager for the Catalyst research fund made some notes on September 15, 2026, at 17:16:06. The fund size is 0 and it has compact receipts. The information comes from the PRE91108 archive. The manager looked at several things, including SEC filings for HITI and BFRI from September 14, 2026. They also saw a report from Dave & Buster's from September 14, 2026. The manager chose some reviews, including one for TSM from September 10, 2026, and one for CAN from September 8, 2026. They also saw some information about EGTX, including a conference on September 11, 2026, and a review on September 16, 2026. The manager also looked at some information about BFRI, including an ITC decision from September 1, 2026. The manager made these notes in 11 panels, each with a unique code, or sha, and a preview of what the panel is about.

The fund in question is the Catalyst Research fund, which has a size of 0 and a timestamp of 2026-09-15T16:01:17.162718+00:00. There are several news updates, including TLX on Sunday, September 13, 2026, regarding FDA approval of Telix's brain cancer imaging drug Pixclara, AVO on Tuesday, September 8, 2026, about Mission Produce's fiscal 2026 third-quarter financial results, ABM on Tuesday, September 8, 2026, about ABM's fiscal third-quarter 2026 results, and ROIV on Tuesday, September 8, 2026, about Roivant's positive results from the Phocus study of mosliciguat. Additionally, there are financial reports from UNFI on September 14, 2026, DRI on July 24, 2026, PPIH on September 9, 2026, MRK on August 7, 2026, and WLTH on September 14, 2026. Other updates include EPM on Thursday, September 10, 2026, declaring a $0.12 per share cash dividend for fiscal Q1, and IPHA on September 10, 2026, with a 6-K filing. There are also HTTP200 hash results for KGF, ASKUL, IPHAnews, and SOBI. The research is for informational purposes only, with a note to read originals and validate strong or new information, and to cash and reverify weak or absent information. There is a conditional receipt for Sobi and Q1-2028, and monitors 165, 168, 167, and 137, and 22 are to be preserved. The sources and dates are available in the job script and journal, and there are no orders.

The fund, called Catalyst, is researching the stocks IONS, MIRM, GIS, and EAT, as well as CAG, with a size of 0. The research is based on data available as of September 15, 2026, at 13:46:05 UTC. The fund manager has reviewed SEC filings for IONS on September 4, 2026, MIRM on September 8, 2026, GIS on July 1, 2026, and EAT on August 12, 2026. A discovery was made on September 9, 2026, that Barclays maintains an overweight rating on Ionis Pharmaceuticals, but lowers its price target to $85. GIS has a conference scheduled for September 8, 2026, at 19:00 UTC, and the fund manager will review the replay. The fund manager will also review earnings for GIS on September 23, 2026, at 13:00 UTC. The baseline for GIS is an EPS of $3.00-3.20 for FY27, with organic growth of -1.5% to +0.5%, and savings of $750 million. The fund manager has chosen to review EAT's investor day on September 17, 2026, at 16:30 UTC, and earnings call on October 28, 2026, at 16:30 UTC. The fund manager will verify the full pipelines and early news for all stocks.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 15, 2026, at 13:46:05 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. The manager also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the manager looked at RSS feeds from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 15, 2026. The manager also checked the FDA website for information on GRAL, which has a panel meeting scheduled for September 23, 2026. The manager noted that SEC filings may lag behind news and that reviews will be done at the following times: September 9 at 12:30 for new morning results, September 10 at 12:30 for LOVE, and September 24 at 12:30 for SFIX after the September 23 AMC. The manager also noted that the GRAL panel meeting on September 23 is not for approval. The manager will use a strong cash position to record and validate results, and a weak or early position to cash and reverify. No automatic orders were placed.

The Catalyst research fund has a size of 0 as of September 15, 2026, at 11:46:04 UTC. Recent news includes TLX on September 13, 2026, where the FDA approved Telix's brain cancer imaging drug Pixclara, which can be found at https://telixpharma.com/news-views/fda-approves-telixs-brain-cancer-imaging-drug-pixclara/. Other news includes AVO on September 8, 2026, about Mission Produce's fiscal 2026 third-quarter financial results at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial, ABM on September 8, 2026, about ABM's fiscal third-quarter 2026 results at https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results, and ROIV on September 8, 2026, about Roivant's positive results from the Phocus study of mosliciguat at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat. Financial reports were also filed by UNFI on September 14, 2026, DRI on July 24, 2026, PPIH on September 9, 2026, MRK on August 7, 2026, and WLTH on September 14, 2026. Additionally, EPM declared a $0.12 per share cash dividend on September 10, 2026, at https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-declares-012-share-cash-dividend-fiscal-q1, and IPHA filed a 6-K report on September 10, 2026, at https://www.sec.gov/Archives/edgar/data/0001628280/000162828026061214/a260910_6k.htm. HTTP requests were successful for KGF, ASKUL, IPHAnews, and SOBI with hashes dda88bf6ef8ad805, e6f0d85c03a37ce6, 63c1ed7a93468887, and d719eca30b8a5a99 respectively. Research is ongoing, with a focus on strong and new information, and a need to read originals and validate. For weak or absent information, cash and reverification are necessary. IPHA has a deadline of September 17, and Sobi has a conditional receipt for Q1 2028. Monitors 165, 168, 167, and 137, and 22 are preserved. Sources and dates can be found in the job script and journal. There are no orders at this time.

The Catalyst fund is for research only on IONS, MIRM, GIS, and EAT, with a size of 0. On September 15, 2026, at 09:31:10 UTC, the fund had the following information: IONS had an SEC filing on September 4, 2026, available at https://www.sec.gov/Archives/edgar/data/874015/000114036126035802/ef20081690_8k.htm. MIRM had an SEC filing on September 8, 2026, available at https://www.sec.gov/Archives/edgar/data/1759425/000175942526000047/mirm-20260902.htm. GIS had an SEC filing on July 1, 2026, available at https://www.sec.gov/Archives/edgar/data/40704/000162828026046337/gis-20260701.htm. EAT had an SEC filing on August 12, 2026, available at https://www.sec.gov/Archives/edgar/data/703351/000070335126000026/eat-20260810.htm. A news scan found the headline that Barclays maintained an overweight rating on Ionis Pharmaceuticals and lowered its price target to $85 on September 9, 2026. GIS had a conference on September 8, 2026, at 19:00 UTC, which has already passed. The fund will review the replay. GIS will have earnings on September 23, 2026, at 13:00 UTC, with a Q&A session, but the first release time is unknown, available at https://investors.generalmills.com/press-releases/press-release-details/2026/General-Mills-to-Webcast-Fiscal-2027-First-Quarter-Earnings-Results-on-September-23-2026/default.aspx. If GIS has stronger organic cash and guidance, the fund will record and validate, but if it has weaker or absent cash, the fund will reverify. There will be no automatic entry, and the dates are for review, not first news. The baseline for July 1, FY27, is an EPS of $3.00-3.20, with organic growth of -1.5% to +0.5% and savings of $750 million. The frozen paper window is from September 16 to September 21, with a calendar out of sample of +0.567% and stress of -2.405%, and N10. The fund will never retune past tests. EAT had an investor day on August 31, 2026, and will have an earnings call on October 28, 2026, with a review at 16:30 UTC. If EAT has stronger organic cash, the fund will record and independently validate, but if it has weaker or absent cash, the fund will reverify. The frozen T5 holdout is -19.2065% and N7, with no automatic trade. The investor-day odds are untested, and static dates are not armed. The fund has four SEC filings, one discovery, two GIS reviews, and two EAT reviews, and will verify full pipelines and early news. The Catalyst fund is for research only, with no orders, as of September 15, 2026, at 09:31:14 UTC.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 15, 2026, at 09:31:12 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. The manager also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the manager looked at news releases from SAIL, KFY, and LOVE, which were published on September 9, 2026, and September 10, 2026. The manager also checked the FDA website for information on GRAL, which has a panel meeting scheduled for September 23, 2026. The manager notes that SEC filings may lag behind news and will review new results on September 9, 2026, at 12:30, September 10, 2026, at 12:30, and September 24, 2026, at 12:30. The manager also notes that the GRAL panel meeting on September 23, 2026, is not an approval meeting. The manager has a strong cash position and will validate and verify it, but will not place any automatic orders.

The fund is called Catalyst Research and its size is 0. It has compact receipts and its origins are in the PRE91108 archive. The current time is 2026-09-15T09:16:09.319732+00:00. There are 11 panels of information. Panel 0 has 70 characters and a SHA, or secure hash algorithm, of cbf74ee0758ce133. Panel 1 has 101 characters and a link to the SEC website for HITI on 2026-09-14. Panel 2 has 98 characters and a link to the SEC website for BFRI on 2026-09-14. Panel 3 has 216 characters and a news headline about Dave & Buster's second quarter 2026 report. Panel 4 has 246 characters and mentions TSM and DATA.L S. Panel 5 has 260 characters and mentions CAN and PLAY. Panel 6 has 353 characters and talks about improved organic cash and credible clinical evidence. Panel 7 has 160 characters and mentions EGTX and MFN. Panel 8 has 206 characters and mentions EGTX conferences. Panel 9 has 99 characters and a link to the USITC website for BFRI. Panel 10 has 341 characters and mentions BFRI and the ITC lifting a suspension on September 1. The raw SHA is 9b95f4fc0a08fd9ff47ca558414291e8ff30af96e4d86b23d98f7d2c8f8c5286.

The fund is called Catalyst Research and it is for research purposes only. The fund size is 0 and the time is 2026-09-15T07:45:59.797567+00:00. There are several news updates: TLX on Sunday, September 13, 2026, announced that the FDA approved Telix's brain cancer imaging drug Pixclara, which can be found at https://telixpharma.com/news-views/fda-approves-telixs-brain-cancer-imaging-drug-pixclara/. AVO on Tuesday, September 8, 2026, announced its fiscal 2026 third-quarter financial results, which can be found at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial. ABM on Tuesday, September 8, 2026, reported its fiscal third-quarter 2026 results, which can be found at https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results. ROIV on Tuesday, September 8, 2026, announced positive results from the Phocus study of mosliciguat, which can be found at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat. There are also several financial filings: UNFI filed a 10-K on September 14, 2026, which can be found at 0001020859-26-000025/unfi-20260801.htm, DRI filed a 10-K on July 24, 2026, which can be found at 0000940944-26-000025/dri-20260531.htm, PPIH filed a 10-Q on September 9, 2026, which can be found at 0001437749-26-029988/ppih20260731_10q.htm, MRK filed a 10-Q on August 7, 2026, which can be found at 0000310158-26-000212/mrk-20260630.htm, and WLTH filed a 10-Q on September 14, 2026, which can be found at 0001628280-26-061848/wlth-20260731.htm. EPM announced a $0.12 per share cash dividend on Thursday, September 10, 2026, which can be found at https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-declares-012-share-cash-dividend-fiscal-q1. IPHA filed a 6-K on September 10, 2026, which can be found at 0001628280-26-061214/a260910_6k.htm. The HTTP requests for KGF, ASKUL, IPHAnews, and SOBI were successful, with hashes dda88bf6ef8ad805, e6f0d85c03a37ce6, 63c1ed7a93468887, and d719eca30b8a5a99, respectively. The research is ongoing, with a focus on strong and new information, and a need to read originals and validate. There are also weak or absent information that needs to be verified. IPHA has a deadline of September 17, and Sobi has a conditional receipt for Q1 2028. The monitors 165, 168, 167, and 137, and 22 are preserved. The sources and dates are in the job script and journal. There are no orders.

A fund manager reviewed six names for primary receipts, replacing 205 with an exit code of 0. The fund is called Catalyst Research and its size is 0. The receipts are compact and originated from the PRE91108 archive. The review occurred on 2026-09-15 at 07:01:06.893963+00:00. The manager analyzed various panels, including one about CNXC with a filing date of 2026-08-14 and a form called SCHEDULE 13G, which is a type of securities filing. Another panel mentioned TBN news about Tamboran delivering first gas sales from the Beetaloo Basin. The manager also looked at a corporate calendar for Tamboran and a news article about Scholar Rock announcing FDA approval of a drug called ISEMBYLD. Additionally, the manager reviewed a blog post from Neovolta about home battery safety and made decisions about stocks, including exiting SRRK and NEOV on certain dates.

The Catalyst fund is currently in research mode only, with a size of 0, as of September 15, 2026, at 05:31:00 UTC. The fund is monitoring the following stocks: IONS, MIRM, GIS, EAT, and CAG. The Securities and Exchange Commission (SEC) filings for these stocks are available at the following links: IONS on September 4, 2026, MIRM on September 8, 2026, GIS on July 1, 2026, and EAT on August 12, 2026. On September 9, 2026, Barclays maintained an overweight rating on Ionis Pharmaceuticals and lowered its price target to $85. GIS had a conference and review on September 8, 2026, at 19:40 UTC, which has already passed. The company will release its earnings on September 23, 2026, at 13:00 UTC, with a question-and-answer session, but the exact time of the first release is unknown. The baseline for GIS is an EPS of $3.00-3.20 for fiscal year 2027, with organic growth of -1.5% to +0.5% and savings of $750 million. The fund will review EAT's investor day on September 17, 2026, at 16:30 UTC, and its earnings call on October 28, 2026, at 16:30 UTC. The fund will verify the full pipelines and early news for these stocks.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 15, 2026, at 05:30:59 UTC. The fund reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. It also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the fund looked at RSS feeds from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 10, 2026. The fund also checked the FDA website for information on GRAL, which has a meeting scheduled for September 23, 2026. The fund will review new morning results on September 9 and 10, and SFIX results on September 24. The GRAL meeting on September 23 is a panel meeting, not an approval meeting. The fund has a strong cash position, which will be recorded and validated, while weak or early positions will be cashed out and reverified. No automatic orders were placed.